The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic arthritis. efficacy and safety of as compared with adalimumab, tumor necrosis factor α inhibitor, in patients who have an inadequate response to nonbiologic disease-modifying antirheumatic drugs are unclear.